Michael Shulman

Michael Shulman

Michael Shulman is an author, writer, newsletter advisor and expert on financial trends and developments.

Michael began his career doing in-depth company and market analysis for a variety of companies, building databases and simulation models to estimate the success of various technologies across a wide range of market segments. He moved “inside” the high-tech community as a manager at high-tech companies including AT&T. Michael was an early private investor in several Internet start-ups, notably XOOM.com, which went public in 1998 and was bought by NBC in 1999.

Michael entered the financial publishing business formally in 2001 as director of research for ChangeWave Research’s institutional research business and as the writer and editor of Hedge Fund Investing. His current newsletters include Options Income Blueprint, Short Side Trader, The New Normal Investor and Madness of Crowds. Click here for more information about these services.

Michael is also the author of Sell Short (John Wiley, 2009) and Made in America: Inside Stories of Success (Otterbourn Publishing, 2013), a book based on four factory visits and a brief overview of the  myths and realities about surrounding US manufacturing. He has been published in a variety of trade and general business publications, including CD-ROM Today, Worth Online, The Motley Fool, Bonjour Paris and the Los Angeles Times and is a frequent guest on CNBC’s “Squawk Box” and Fox Business.

Recent Articles

5 Retail Stocks to Short

Retailers have been some of the best performers in the past few months, but these retail stocks are due for a fall.

11 Market Predictions for 2011

Start preparing yourself for the bumpy ride in the year ahead with these market predictions and trading ideas for 2011.

When to Exit an Options Trade

Knowing when to exit an options trade is the most difficult part of trading. I'll help you to understand 'when to hold 'em' and 'when to fold 'em.'

Will the Market Remain Stuck for the Rest of the Year?

The S&P 500 is range bound between 1,125 (support) and 1,225 (resistance).

Election is Bad New for Drug Stocks

The gridlock resulting from last week’s election will also create uncertainty about health care, taxes, financial reform, pension reform, etc.